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Abstract
Background: The implementation of combined radiochemotherapy (RCHT) with temozolomide
(TMZ) has lead to a significant increase in overall survival times in patients with Glioblastoma
multiforme (GBM), however, outcome still remains unsatisfactory.
The majority of GBMs show an overexpression and/or amplification of the epidermal growth factor
receptor (EGFR). Therefore, addition of EGFR-inhibition with cetuximab to the current standard
treatment approach with radiotherapy and TMZ seems promising.
Methods/design: GERT is a one-armed single-center phase I/II trial. In a first step, dose-escalation
of TMZ from 50 mg/m2 to 75 mg/m2 together with radiotherapy and cetuximab will be performed.
Should safety be proven, the phase II trial will be initiated with the standard dose of 75 mg/m2 of
TMZ. Cetuximab will be applied in the standard application dose of 400 mg/m2 in week 1, thereafter
at a dose of 250 mg/m2 weekly. A total of 46 patients will be included into this phase I/II trial.
Primary endpoints are feasibility and toxicity, secondary endpoints are overall and progression-free
survival. An interim analysis will be performed after inclusion of 15 patients into the main study.
Patients' enrolment will be performed over a period of 2 years. The observation time will end 2
years after inclusion of the last patient.
Discussion: The goal of this study is to evaluate the safety and efficacy of combined RCHT-
immunotherapy with TMZ and cetuximab as first-line treatment for patients with primary GBM.
Background
Glioblastoma multiforme (GBM) is the most frequent pri-
mary malignant brain tumor in adults. Until recently, the
standard treatment approach in patients with GBM was
neurosurgical resection, as radical as possible, followed by
postoperative radiotherapy (RT). However, in spite of
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technical advances in surgery and radiotherapy, overall
survival still remained unsatisfactory with median overall
survival times of 9–12 months [1,2].
Over the last decade, a number of clinical investigations
on combined radio-chemotherapy (RCHT) after neuro-
surgical resection have been conducted. A large rand-
omized trial performed by the Neuro-Oncology Working
Group of the German Cancer Society evaluated combined
RCHT with nimustine plus teniposide versus nimustine
plus cytarabine and could obtain a median overall sur-
vival time of 16.5 months in patients with GBM [3].
Temozolomide (TMZ), an oral alkylating agent, had dem-
onstrated antitumor activity as a single-agent treatment in
recurrent GBM [4-6].
In a pilot phase, the feasibility of concomitant administra-
tion of TMZ and fractionated RT followed by 6 cycles of
adjuvant TMZ was demonstrated and one could suggest
that this combined treatment modality would offer signif-
icant benefit for patients with GBM [7]. At the Depart-
ment of Radiation Oncology at the University of
Heidelberg a trial evaluating combined RCHT with TMZ
in a dosage of 50 mg/m2 5 days per week was conducted,
without adjuvant application of TMZ; we observed a
median overall survival time of 19 months, and treat-
ment-related toxicity was low [8].
A large randomized trial conducted by the EORTC evalu-
ated the outcome after combined RCHT with TMZ fol-
lowed by adjuvant TMZ application as opposed to RT
alone; in patients treated with RCHT, overall survival was
significantly increased to 14.6 months as compared to RT
alone with 12.1 months [9].
Treatment-related toxicity was relatively high in the com-
bined treatment arm with 14% of patients presenting with
WHO Grade 3 or 4 hematologic toxicities as compared to
7% in the RT-group. Additionally, RT was interrupted or
delayed in 32% of the RCHT-patients, and only 47% of all
RCHT patients completed the planned 6 cycles of adju-
vant TMZ-application. However, the significant increase
in overall survival can be considered a major progress and
thus the current standard for patients with GBM is consid-
ered RT together with the concomitant and adjuvant
application of TMZ.
In spite of these advances in outcome, overall survival is
still dissatisfactory. Therefore, novel approaches must be
implemented into clinical evaluation. Recently, a number
of molecular targeting agents have been developed and
evaluated in early clinical trials. The main ulterior motive
for these therapies is that by intervening into molecular
mechanisms the treatment resistance of cancer cells may
be overcome, and an amplification of the RCHT-response
might be achieved.
To date, several targets have been identified and include
vascular-endothelial growth factor (VEGF), platelet-
derived growth factor (PDGF), agents targeting compo-
nents of the Ras- and Akt-mediated pathways, as well as
the human epidermal growth factor receptor (HER). All of
these are known to play a key role in tumorigenesis and
disease progression [10].
The HER-family consists of four distinct receptors: HER1/
EGFR (epidermal growth factor receptor), HER2, HER3
and HER4 [11,12]. The EGFR gene is a proto-oncogene
that is often amplified in a variety of human tumors
[13,14]. The EGFR-gene is located on chromosome 7 and
encodes for a 170 kD transmembrane glycoprotein with
intrinsic tyrosine-kinase activity [15,16]. The receptor
molecules consist of an extracellular ligand binding
domain and an intracellular tyrosine kinase that is acti-
vated via conformational change in the intracellular pro-
tein domain due to extracellular ligand binding and
receptor dimerization; the activation of the tyrosine
kinase results in phosphorylation of intracellular sub-
strate proteins, kicking off an intracellular reaction cas-
cade regulating cell function and division, apoptosis,
adhesion, motility and neoangiogenesis [17]. There are
also several mutant HER1/EGFR, the most common one
being EGFRvIII, which is constitutively activated and leads
to downstream intracellular cascade activation without
ligand binding [18-20].
In GBM, the EGFR gene is one of the most frequently
amplified proto-oncogenes; expression of the EGFR-pro-
tein has been observed in 24–95% of cases [13,14,21]
(Table 1).
The real prognostic significance remains unclear to date.
However, in a number of other cancers including breast,
bladder, esophagus, cervix, ovary, lung and head and neck
the overexpression of EGFR has been reported to be a poor
prognostic factor [22-24].
A number of small molecules acting as tyrosine-kinase
inhibitors (TKIs) have been evaluated in the treatment of
GBM. A subgroup of patients demonstrated a response to
these agents, however, no correlation with overall survival
could be demonstrated [25,26]. A recent publication by
Mellinghoff et al. could identify patients expressing
EGFRvIII as well as the tumor suppression protein PTEN
showing a greater response to the TKIs [25].
Cetuximab is a monoclonal antibody binding specifically
to EGFR and thus inhibiting downstream signal transduc-
tion pathways [27]. It has been shown that cetuximabBMC Cancer 2006, 6:133 http://www.biomedcentral.com/1471-2407/6/133
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enhances radiosensitivity, promotes radiation-induced
apoptosis, decreases cell proliferation, inhibits radiation-
induced damage repair and inhibits tumor angiogenesis
[23].
A number of clinical studies with the EGFR-antibody
cetuximab have shown that its application is efficacious
and tolerable, with the most common toxicity being
acneiform rash. In general, allergic reactions including
anaphylaxis could be a potential side effect. A number of
phase I and II clinical studies have been conduced with
cetuximab as a single agent and have lead to response
rates up to 12% and additional stable disease rates up to
32% of all patients with advanced non small cell lung can-
cer (NSCLC), ovarian cancer, head and neck cancer and
colorectal cancer [23]. A major trial evaluating a combina-
tion of radiotherapy plus cetuximab versus radiotherapy
alone in patients with locoregionally advanced squamous
cell carcinoma of the head-and-neck could demonstrate a
significant increase in local tumor control rates as well as
in overall survival. In a number of the studies conducted,
EGFR-overexpression correlated significantly with
patients' outcome [22,23,28,29].
Therefore, two main rationales have lead to the initiation
of the present study protocol:
1. Overexpression of EGFR has been shown to influence
outcome of EGFR-inhibition in patients with extracranial
tumors.
2. The majority of GBM show overexpression of EGFR as
wildtype or as mutant.
Therefore, the present study protocol evaluates EGFR-
inhibition with cetuximab together with the standard
radiochemotherapeutic treatment consisting of RCHT
with TMZ for patients with primary GBM.
Methods/design
Study design
The study is designed as a one-armed study evaluating the
feasibility and toxicity of combined radiochemo-immu-
Table 1: Percentage of reported EGFR-amplification/overexpression in patients with glioblastoma multiforme: Literature overview. 
Abbreviations: Southern Blot (SB), Immunohistochemistry (IHC), Western Blot (WB), Polymerase Chain Reaction (PCR), In situ 
hybridization (ISH), Fluorescence In-Situ Hybridization (FISH).
Author 
(Reference)
Year of publication Patients (n) Patients with 
EGFR-
amplification (n)
Patients with 
EGFR-
overexpression (n)
Method of EGFR 
evaluation
Quan et al. 2005 107 36 (32%) - ISH
Mellinghoff et al. 2005 25 12 (48%) - FISH, PCR
Shinojima et al. 2003 87 40 (46%) - SB, IHC
Schmidt et al. 2002 91 26 (29%) - PCR
Barker et al. 2001 162 - 53 (33%) IHC
Simmons et al. 2001 110 - 39 (35%) IHC
Chakravarti et al. 2001 56 - 23 (41%) WB
Smith et al. 2001 111 46 (41%) - FISH, PCR
Yoon et al. 2001 36 13 (36%) 12 (33%) PCR, IHC
Korshunov et al. 1999 168 - 102 (61%) IHC
Olson et al. 1998 70 19 (27%) - SB
Bouvier-Labit et al. 1998 63 - 22 (35%) IHC
Newcomb et al. 1998 80 - 28 (35%) IHC
Korkopopoulou et al. 1997 37 - 17 (64%) IHC
Rainov et al. 1997 71 - 54 (76%) IHC
Liu et al. 1997 63 31 (49%) - SB
Waha et al. 1996 54/62 18 (33%) 32 (52%) PCR, IHC
Zhu et al. 1996 55 - 39 (71%) IHC
Diedrich et al. 1995 32/22 13 (41%) 19 (86%) ISH
Kordek et al. 1995 30 - 10 (33%) IHC
Schober et al. 1995 21 13 (62%) - PCR, IHC
Schlegel et al. 1994 42 19 (45%) 27 (64%) SB, PCR, WB
Hiesinger et al. 1993 17 - 4 (24%) IHC
Hurtt et al. 1992 19 6 (32%) - Dot blot
Jaros et al. 1992 20 - 19 (95%) IHC
Torp et al. 1992 20 8 (40%) - SB
Bigner et al. 1988 48 20 (42%) NR SB, slot blot
Wong et al. 1987 47 20 (43%) - SB, slot blotBMC Cancer 2006, 6:133 http://www.biomedcentral.com/1471-2407/6/133
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notherapy with TMZ and cetuximab. The trial can be
divided into two phases: During the Phase I part, dose
escalation of TMZ from 50 mg/m2 to 75 mg/m2 together
with RT and cetuximab will be performed. Thereafter, the
Phase II part of the trial will be initiated with a daily total
dose of 75 mg/m2 with concomitant RT and cetuximab.
Study objectives
Primary endpoint of the study is feasibility and toxicity of
combined trimodal therapy with TMZ, cetuximab and
radiotherapy. According to the current standard treatment
for patients with GBM, about 10% off all patients develop
WHO Grade III and IV toxicity [9]. We defined a toxicity
rate of 30% for WHO Grade III and IV side effects as over-
all acceptable for this study.
Secondary endpoints include overall survival, progres-
sion-free survival and quality of life.
Trial organization
The study protocol of GERT was designed by the study ini-
tiators at the Department of Radiation Oncology at the
University of Heidelberg. It is an investigator-initiated
trial (IIT); trial medication is provided by Merck KgaA in
Darmstadt, Germany. The trial is conducted at the Depart-
ment of Radiation Oncology at the University of Heidel-
berg.
Coordination
The overall coordination is performed by the Department
of Radiation Oncology at the University of Heidelberg,
and this department is responsible for overall trial man-
agement, trial registration, database management and
quality assurance. The study monitoring according to the
guidelines of Good Clinical Practice (GCP) is performed
by the Koordinierungszentrum für Klinische Studien
(KKS), University of Heidelberg. Biometrical data analysis
is conducted together with the Department of Biostatistics
of the German Cancer Research Center (dkfz).
Investigators
The study investigators are experienced radiation oncolo-
gists specialized in the treatment of patients with GBM.
Patients will be recruited and treated by the physicians of
the Department of Radiation Oncology of the University
of Heidelberg.
Patient selection
Inclusion criteria into the study protocol include:
- patients ≥18 and < 70 years of age
- Karnofsky Performance Score ≥60
- histologically confirmed supratentorial GBM
- interval between primary diagnosis and registration for
the study < 4 weeks
- patients will be included according to the incidental gen-
der distribution for patients with GBM of / 2:3
- adequate blood values (not older than 14 days prior to
initiation of RCHT)
- neutrophil count (ANC) ≥1500/mm3 or white blood
cells (WBC) ≥2000/mm3
- platelets ≥100.000/mm3
- hemoglobin ≥10 g/dL
- BUN <1.5 times the upper range
- Total and direct bilirubin <1.5 times the upper labora-
tory limit
- Adequate liver enzymes <3 times the upper laboratory
limit
- Life expectancy >12 weeks
- Written informed consent
Additionally, the combined treatment with radiotherapy
and TMZ would be the standard treatment recommended
to be performed in the patients included into the study.
Exclusion criteria
￿ refusal of the patients to take part in the study
￿ previous radiotherapy of the brain or chemotherapy
with DTIC or TMZ
￿ known allergy against extrinsical proteins
￿ previous chemotherapy or therapy with an EGFR-inhib-
itor
￿ Previous antibody therapy
￿ Patients who have not yet recovered from acute toxicities
of prior therapies
￿ Acute infections requiring systemic application of anti-
biotics
￿ Frequent vomiting or a medical condition preventing
the oral application of TMZ
￿ Clinically active kidney-liver or cardiac diseaseBMC Cancer 2006, 6:133 http://www.biomedcentral.com/1471-2407/6/133
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￿ Known carcinoma < 5 years ago (excluding Carcinoma
in situ of the cervix, basal cell carcinoma, squamous cell
carcinoma of the skin)
￿ HIV
￿ Pregnant or lactating women
￿ Participation in another clinical study
Statistical calculations for trial sample size
The trial is evaluating in its Phase 1 part the tolerability of
the TMZ dose of 75 mg/m2 together with cetuximab in a
two step escalation with a maximum of 12 patients, while
evaluation in its Phase II part the following two hypothe-
ses:
1. non-tolerable toxicity H0: existence of no tolerable tox-
icity, i.e. TR >30%, NTR ≤70%
2. tolerable toxicity H1: existence of tolerable toxicity, i.e.
TR < 10%, NTR ≥90%
with RT denoting the rate of toxicity and NTR the rate of
non-toxicity. Therefore, the trial consists of a dose finding
part (Phase I) and a feasibility part (Phase II).
These two hypothesis will be examined using a two-step
optimal phase II design according to Simon et al. [30] in
the defined patient population with a significance level of
5% (alpha = 0.05) and a power of 90% (beta = 0.1) with
a one-armed analysis in this single arm trial.
To demonstrate tolerability of the toxicity with a hypoth-
esis-test between NONTOX of 70% versus the anticipated
NONTOX of 90% within a One-Step-Phase II Design, 36
evaluable patients are required (NCSS PASS 2000).
We calculated a drop-out rate of 10%, and therefore a pro-
jected patient number of 40 is planned.
With inclusion of the 6 patients for the dose-finding part
of the protocol, a maximum of 46 patients will be
included into the study.
Recruitment will be carried out over 2 years and a follow-
up time of 1 year per patient is required to evaluate the
primary endpoint.
Overall survival will be determined as the time span
between primary diagnosis and death of lost to follow-up
(censored observation). Progression-free survival will be
determined as the time span between start of the treat-
ment and tumor progression or death, whatever occurred
first or an event which characterises a censored observa-
tion.
The trial consists of a dose-finding study (part 1; Phase I)
followed by a Phase II component.
Step 1
3 patients are treated with combined RCHT (RT at dose
level 1 (DL1) with a total dose of 60 Gy in 2 Gy single frac-
tions + TMZ 50 mg/m2/day, 6 weeks)
Cetuximab (ERBITUX®) is applied in a dose of 400 mg/m2
in week 1, thereafter weekly at 250 mg/m2 week during
the course of RCHT.
Adjuvant treatment: 6 cycles of TMZ 150 mg/m2/day for 5
days, every 28 days (q28d)
If 2 out of 3 patients develop DLT, the study will be
stopped. If 1 out of 3 patients develops DLT, three more
patients will be included at a dose of 50 mg/m2 TMZ. Dose
escalation is halted if two ore more patients develop DLT.
Step 2
3 Patients are treated with combined RCHT (RT with GD
60 Gy, ED 2.0 Gy + TMZ 75 mg/m2/day, 6 weeks)
Cetuximab (ERBITUX®) 400 mg/m2 in week 1, thereafter
at a dose of 250 mg/m2 weekly during RCHT.
Adjuvant treatment: 6 cycles of TMZ 150 mg/m2/day for 5
days, every 28 days (q28d).
If DLT occurs in one patient additional three patients will
be treated at DL 2. If 2 or more patients develop DLT, DL
1 will be the recommended dose for the phase II part of
the study the study.
Adverse events
The investigators will report all Adverse Events (AE)
immediately to the sponsor or his legal representative
except for those that the protocol or investigator's bro-
chure identifies as not requiring immediate reporting.
An "adverse event" is any untoward medical occurrence in
a patient or clinical trial subject administered a medicinal
product and which does not necessarily have a causal rela-
tionship with this treatment.
Serious adverse events (SAE) are any untoward medical
occurrence of effect that at any dose results in death, is life-
threatening, requires hospitalization or prolongation of
existing inpatients' hospitalization, results in persisting or
significant disability or incapability, or is a congenital
abnormality or birth defect.BMC Cancer 2006, 6:133 http://www.biomedcentral.com/1471-2407/6/133
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For all serious adverse events, the documents and patient
data must be verified by the responsible study personnel.
Patients' toxicities are to be classified and documented
according to the NCI Common Toxicity Criteria (CTC).
Toxicity is documented weekly during RCHT and prior to
every application of Cetuximab as well as at every follow-
up visit.
Medication
All TMZ applications are provided by the pharmacy of the
University of Heidelberg. Cetuximab is provided by Merck
KGaA, Darmstadt, and is stored until clinical application
by the pharmacy of the University of Heidelberg. All study
medication is prepared especially for each patient regis-
tered into the study and is delivered to the Department of
Radiation Oncology at short notice before administra-
tion.
Monitoring
Monitoring is performed by the Klinische Koordi-
nierunszentrum für Studien (KKS) of the University Hos-
pital in Heidelberg according the guidelines of Good
Clinical Practice (GCP) and the German law on drug
safety (Arzneimittelgesetz, AMG).
Ethics, informed consent and safety
For the present study the Eudract-Number 2005-003911-
63 has been obtained. The final study protocol has been
approved by the ethics committee of the University of
Heidelberg, Heidelberg, Germany (Protocol Number
AFmo-323/2005 [31]) as well as by the Paul Ehrlich Insti-
tute (PEI; registration number 119/01). This protocol fol-
lows all requirements of the Declaration of Helsinki in the
recent German version (Somerset West Version, 1996).
The study protocol is in accordance with the principles of
Good Clinical Practice (GCP) guidelines and the Federal
Data Protection Act. The trial has been initiated and will
be carried out following all local legal and regulatory
requirements. The medical secrecy act is also followed.
Of each patient recruited into the study, written informed
consent is essential prior to inclusion into the study after
extensive information about the intent of the study, the
study regimen, potential associated risks and side effects
as well as potential alternative therapies. Until the patient
has given written informed consent, no action aiming at
inclusion into the study protocol, especially any diagnos-
tic measures required, will be taken.
Quality of life-assessment
Assessment of quality of life is one of the secondary objec-
tives of the trial. The EORTC QLQ30 is a general measure
of quality of life in cancer patients. The questionnaire con-
sists of 9 multi-item scales: five functional scales (physi-
cal, role, cognitive, emotional and social), three symptom
scales (fatigue, pain and nausea/vomiting) as well as glo-
bal health and quality of life scale [32]. Specific symptoms
including dyspnoea, insomnia, anorexia, constipation,
diarrhoea and financial impact are measure as six single
items. This questionnaire has been used widely in studies
with cancer patients and is able to distinguish between
individuals with metastatic and non-metastatic disease, as
well as between patients at different stages of their illness.
Previous studies have proven this tool to have good inter-
nal consistency (alpha > 0.70) and good test-re-test-relia-
bility (0.80 to 0.90) [33].
This test will be performed at the initiation of RCHT, dur-
ing the course of the treatment and at every follow-up
visit.
Follow-up
Patients are seen for follow-up 6 weeks after completion
of RCHT with cetuximab, thereafter in three-months
intervals or as needed clinically. During adjuvant treat-
ment, blood values will be evaluated weekly.
All follow-up visits include complete neurological assess-
ment as well as contrast-enhanced MRI- and/or CT-scans.
Quality of life assessment will be performed at each fol-
low-up visit.
Additional examinations including FDG- or FLT-PET will
be scheduled as required.
Treatment at tumor progression
In order to distinguish between radiation-induced side
effects and tumor progression, FDG-PET and FLT-PET
examinations will be scheduled as required.
In case of tumor recurrence during combined RCHT with
cetuximab or during adjuvant treatment with TMZ, this
therapy will be stopped.
In every case of recurrence, the possibility of neurosurgical
intervention will be evaluated. Additionally, it will be
evaluated whether re-irradiation can be applied safely;
moreover, treatment with standard chemotherapeutic
substances will be evaluated in every patient.
Interim analysis
An interim analysis is planned after inclusion of 15
patients into the main study. The trial can be stopped
should it be obvious that the alternative hypothesis of a
tolerable toxicity rate
H1:R≤10% i.e. NONTOX-Rate ≥90%BMC Cancer 2006, 6:133 http://www.biomedcentral.com/1471-2407/6/133
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cannot be achieved, i.e. should the number of WHO grade
III and IV toxicities be larger than 7 (meaning 8 or more
Grade III and IV toxicities). In this case the study will be
closed due to "futility".
Recruitment for the study will be conducted during a
period of 2 years. Final evaluation of the primary and sec-
ondary endpoints of the study will be performed 1 year
after inclusion of the last patient.
The formal end of the study is defined as the end of the
observation period of the last patient included into the
study.
Discussion
The trial is carried out as a single center trial at the Univer-
sity of Heidelberg, Department of Radiation Oncology in
Germany.
The department has a strong focus and neuro-oncology
[8,34-46]. The department offers all techniques of con-
ventional RT as well as all modern forms of high-precision
RT including fractionated stereotactic radiotherapy (FSRT)
and intensity modulated radiotherapy (IMRT) [47-53].
Extensive experience in combined multimodality treat-
ment approaches is provided as well as three wards for
patients requiring hospitalization. All other departments
of the University Hospital of Heidelberg including neuro-
surgery and nuclear medicine are in close vicinity offering
all medial care potentially needed. Therefore, all essential
requirements to conduct the present study are met at our
department.
With the present trial, we aim at improving outcome in
patients with GBM by adding the promising molecular
target of EGFR-inhibition with cetuximab to the current
treatment standard for patients with GBM consisting of
radiotherapy combined with TMZ.
Abbreviations
CRO Clinical Research Organization
EGFR Epidermal Growth Factor Receptor
GBM Glioblastoma multiforme
GCP Good Clinical Practice
RCHT Radio-Chemotherapy
TMZ Temozolomide
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